FDA approves prostate cancer radiotherapy Pluvicto developed by Novartis

March 26, 2022

Life Sciences Voice Top Five Newsletter

April 17, 2023

Life Sciences Voice Top Five Newsletter

October 17, 2023

Must Read

Top 10 Trends Reshaping Pharmaceutical Sales

August 11, 2026

MoonLake Reports Positive Phase 3 Results for Sonelokimab in Psoriatic Arthritis

August 11, 2026

Jazz Pharmaceuticals to Acquire Actio for Up to $1.32 Billion to Add KCNT1 Epilepsy Therapy

August 11, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Biogen’s Phase 2 Diranersen Data Shows Reduced Cognitive Decline in Alzheimer’s Disease

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

MoonLake Reports Positive Phase 3 Results for Sonelokimab in Psoriatic Arthritis

Merck’s Tulisokibart Misses Phase 2 Endpoint in SSc-ILD but Meets Goals in HS Trial

After phase 3 data ended blockbuster hopes, GSK eliminated a major cough medication candidate

Hansoh Announces Fresh Phase 3 Victory For Priority ADC

Jazz Pharmaceuticals to Acquire Actio for Up to $1.32 Billion to Add KCNT1 Epilepsy Therapy

Actimed Reclaims Rights to Wasting Disease Drug; $126M Faraday Deal Dead

The biggest pharmaceutical deal ever would be the “unlikely” AstraZeneca-BMS mega-merger

Claryx Appears From Stealth to Deal with the $45B Hospital-Acquired Infections Issue

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

Top 10 Trends Reshaping Pharmaceutical Sales

Top 10 Technologies Accelerating Drug Discovery

What an Autonomous Clinical Trial Might Look Like by 2030

From Data-Rich to Insight-Rich: Pharma’s Next Transformation

Tag: JenaValve

FDA Approves JenaValve Trilogy System as First Minimally Invasive Implant for Severe Aortic Regurgitation

Editor Picks

FDA approves prostate cancer radiotherapy Pluvicto developed by Novartis

Life Sciences Voice Top Five Newsletter

Life Sciences Voice Top Five Newsletter

Must Read

Top 10 Trends Reshaping Pharmaceutical Sales

MoonLake Reports Positive Phase 3 Results for Sonelokimab in Psoriatic Arthritis

Jazz Pharmaceuticals to Acquire Actio for Up to $1.32 Billion to Add KCNT1 Epilepsy Therapy

Hot Topics

About Us

Follow Us